Proactive Investors - Run By Investors For Investors

Actinogen moves to next stage of Alzheimer's treatment trials

Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may offer a novel new treatment of Alzheimer's disease.

Managing Director Dr Bill Ketelbey says the drug, which treats increased cortisol levels that may decrease cognitive ability, could be "an enormously valuable asset" even though it only treats, rather then cures Alzheimer's.

 
Meet Kazia Therapeutics Ltd, Adalta Ltd, Peninsula Energy Ltd, Theta Gold Mines Ltd and Argonaut Resources NL at our event, Sydney , 18 February 2019. Register here »
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use